Clinical trials: Secondary Immune Deficiency
HIV Infections, Cancer, Second Primary
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
We hypothesize that micronutrient fortified probiotic yogurt can improve nutritional status and enhance immunity parameters in subjects HIV/AIDS and other immunodeficiencies.
- Trial name
- NCT00517803
- Testing
- Probiotic Yogurt B: with various micronutrients, Probiotic Yogurt A: Kaiser micronutrients, Probiotic yogurt C: with basic micronutrients
- Where
- Canada
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
HIV, AIDS
Testing a Secondary Prevention Intervention for HIV-Positive Black Young Men Who Have Sex With Men
The proposed research study aims to conduct a culturally-based secondary prevention intervention targeted toward HIV-positive Black young men who have sex with men (B-YMSM) to explore (1) feasibility and acceptability (Trial 1…
- Trial name
- NCT01751594
- Testing
- MOVE Intervention, H4L Comparison Intervention
- Where
- 5 sites in United States
- Volunteers
- 92 people
- Sponsor
- University of North Carolina, Chapel Hill
Immunodeficiency Secondary to Organ Transplantation
Evolution of Interleukin 7, Fat Mass and Metabolic Profile Before and After Transplantation
Three different white adipose tissue-related disorders, whether due to its excess (obesity), absence (lipoatrophies) or aberrant distribution (lipodystrophies), are paradoxically able to induce metabolic insulin resistance…
- Trial name
- IL-7tran (NCT01414660)
- Testing
- transplantation
- Where
- 5 sites in France
- Volunteers
- 49 people
- Sponsor
- University Hospital, Lille
HIV Infections
Amprenavir/Ritonavir or Saquinavir/Ritonavir in HIV-Infected Subjects Following Failure With Kaletra as Their Second Protease Inhibitor
The purpose of this study is to study the safety and efficacy of Amprenavir/ritonavir or saquinavir/ritonavir in HIV infected patients that have failed Kaletra as their second protease inhibitor based HAART.
- Trial name
- NCT00038519
- Testing
- Amprenavir/ritonavir, Saquinavir/ritonavir
- Where
- 52 sites in United States, Argentina and 8 more
- Volunteers
- 16 people
- Sponsor
- Abbott
HIV/AIDS
"Switch Either Near Suppression Or THOusand"
This trial addresses the question of the viral load (VL) threshold for switching from first-line to second-line antiretroviral therapy (ART). The WHO currently sets the threshold at 1000 copies/mL.
- Trial name
- SESOTHO (NCT03088241)
- Testing
- switch
- Where
- 8 sites in Lesotho
- Volunteers
- 80 people
- Sponsor
- Niklaus Labhardt
Diphtheria, Tetanus
DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and Uninfected Infants
This study aims to assess and confirm the adequate immunogenicity and safety profile of the Sanofi Pasteur's DTaP-Hep B-IPV-PRP-T fully liquid combined hexavalent vaccine administered in HIV-exposed uninfected infants and in…
- Conditions
- Diphtheria, Tetanus, Pertussis, Hepatitis B
- Trial name
- NCT02817451
- Testing
- Hexaxim®: DTaP-IPV-HB-PRP-T Combined Vaccine
- Where
- South Africa
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
HIV Infection, Recurrent Non-Small Cell Lung Carcinoma
Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection
This phase I trial studies the side effects and best dose of erlotinib hydrochloride in treating non-small cell lung cancer that has spread to other parts of the body or cannot be removed by surgery in patients with human…
- Conditions
- HIV Infection, Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer
- Trial name
- NCT02134886
- Testing
- Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 5 sites in United States
- Volunteers
- 48 people
- Sponsor
- National Cancer Institute (NCI)
Humoral Primary Immunodeficiencies (PIDs), Secondary Form of Humoral Immunodeficiencies
Study of Populations at Risk of Developing Chronic Hepatitis Linked to Chronic Enteric Virus Infection in Patients With Primary Immunodeficiency and Secondary Humoral Deficiency
Dysimmune and specially hepatic immuno-pathological processes are frequent in patients with PIDs (primary immune deficiencies), particularly but not exclusively in patients with humoral defects.
- Conditions
- Humoral Primary Immunodeficiencies (PIDs), Secondary Form of Humoral Immunodeficiencies, Combined Immunodeficiency (CID), Severe Combined Immunodeficiency (SCID)
- Trial name
- EVAH (NCT06659588)
- Testing
- Plasma, urine and stool collection
- Where
- 3 sites in France
- Volunteers
- 200 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Chronic Lymphocytic Leukaemia (CLL), Multiple Myeloma (MM)
Developing a Patient-Reported Outcome (PRO) Screening Measure for Infections and Measuring Quality of Life in Hematological Patients With Secondary Immunodeficiency (SID) Across the Treatment Trajectory - The PRO SID Project
The goal of this observational study is to improve the treatment of hematological patients with secondary immunodeficiency (SID) by developing a patient-reported outcome (PRO) instrument to detect clinically diagnosed infections.
- Conditions
- Chronic Lymphocytic Leukaemia (CLL), Multiple Myeloma (MM), Secondary Immunodeficiency (SID)
- Trial name
- PRO-SID (NCT06821880)
- Where
- 5 sites in Austria, Germany
- Volunteers
- 120 people
- Sponsor
- Medical University Innsbruck
Hiv
HIV-1 Subtype-specific Drug Resistance in Patients Failing Dolutegravir (DTG) Based Regimen
This is a prospective observational study enrolling People Living with HIV (PLHIV) who are on a Dolutegravir-based AntiRetroviral Treatment (ART) regimen and experiencing virologic failure.
- Trial name
- DTG-Resist (NCT06285110)
- Where
- 22 sites in Argentina, Brazil and 14 more
- Volunteers
- 1,103 people
- Sponsor
- University of Bern
HIV Infections
Tenofovir-lamivudine-dolutegravir Combination as Second-line ART: a Randomised Controlled Trial
The strategy to support virological suppression on second-line antiretroviral treatment (ART) includes the provision of ART that has a low pill burden, good tolerability, low toxicity, is easily monitored, has a high barrier to…
- Trial name
- ARTIST (NCT03991013)
- Testing
- Dolutegravir 50 mg
- Where
- South Africa
- Volunteers
- 192 people
- Sponsor
- University of Cape Town
Secondary Antibody Deficiency
Switched Memory B-cells as a Marker for Humoral Immune System Recovery in Patients With Secondary Antibody Deficiency Due to Hematological Malignancies
Current treatment for patients with secondary antibody deficiency (SAD) is Immunoglobulin replacement therapy (IGRT). There are currently no clinical guidelines for IGRT discontinuation in patients with SAD.
- Trial name
- SAD (NCT05612607)
- Testing
- Immunoglobulin replacement therapy (IGRT)
- Volunteers
- 100 people
- Sponsor
- Ottawa Hospital Research Institute
Pancreatic Cancer, Thyroid Cancer
Integrated Cancer Repository for Cancer Research
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer…
- Conditions
- Pancreatic Cancer, Thyroid Cancer, Lung Cancer, Esophageal Cancer
- Trial name
- iCaRe2 (NCT02012699)
- Where
- 42 sites in United States
- Volunteers
- 999,999 people, healthy volunteers welcome
- Sponsor
- University of Nebraska
HIV-1-infection
Study to Evaluate the Pharmacokinetics (PK), Safety, and Efficacy of B/F/TAF in Human Immunodeficiency Virus (HIV)-1 Infected, Virologically Suppressed, Pregnant Women in Their Second and Third Trimesters
The primary objective of this study is to evaluate the steady state PK of bictegravir (BIC) and confirm the dose of BIC/emtricitabine/tenofovir alafenamide (B/F/TAF) 50/200/25 mg fixed dose combination (FDC) in HIV-1 infected…
- Trial name
- NCT03960645
- Testing
- B/F/TAF
- Where
- 8 sites in United States, Dominican Republic and 1 more
- Volunteers
- 62 people
- Sponsor
- Gilead Sciences
HIV Infection
Third Line Antiretroviral Treatment Optimization in Sub-Saharan Africa
Thilao is a multi-country, phase 2b, non-randomized study, in Burkina Faso, Cote d'Ivoire, Mali and Senegal, West Africa. HIV-1 adults with 2nd-line ART virologic failure (plasma HIV-1 RNA >1000 copies/ml) will be recruited and…
- Trial name
- THILAO (NCT02025868)
- Testing
- adherence reinforcement, Antiretroviral Therapy Darunavir/r + Raltegravir + 2 NRTIs (as chosen by the investigators)
- Where
- 7 sites in Burkina Faso, Côte d’Ivoire and 2 more
- Volunteers
- 201 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Hypogammaglobulinemia, Acquired
Immunoglobulin for Hypogammaglobulinemia Due to Chimeric Antigen Receptor T Cell Therapy
Chimeric antigen receptor (CAR) T cells are special immune cells taken from a patient and changed in a lab to help them find and attack cancer cells.
- Trial name
- ICART (NCT06989541)
- Testing
- Immune Globulin Intravenous (Human), 10%, Immune Globulin Subcutaneous (Human), 20% Solution
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- University of Alberta
Multiple Sclerosis
Prospective Stratification of Infectious Risks in Multiple Sclerosis
This monocentric study is to identify factors that increase the susceptibility for infections and establish a questionnaire-based infection score that allows a prospective stratification for infectious risks in patients with…
- Trial name
- InRIMS (NCT04036097)
- Testing
- MS-adapted AWIS questionnaire (MS-AWIS), infection diary (MS-AWIS diary)
- Where
- Switzerland
- Volunteers
- 298 people
- Sponsor
- University Hospital, Basel, Switzerland
Cervical Cancer, Human Papillomavirus (HPV) Infection
Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India
Cervical cancer (CC) remains one of the most common malignancies among women in India, with nearly 100,000 women diagnosed annually and over 60,000 preventable deaths annually.
- Conditions
- Cervical Cancer, Human Papillomavirus (HPV) Infection, Human Immunodeficiency Virus (HIV) Infection
- Trial name
- SAKHI (NCT07209917)
- Testing
- SAKHI HPV Intervention, Enhanced Standard of Care (SOC+)
- Where
- 4 sites in India
- Volunteers
- 348 people
- Sponsor
- University of California, Irvine
Visceral Leishmaniosis, HIV-infection/Aids
Prophylaxis of Visceral Leishmaniasis Relapses in HIV Co-infected Patients With Pentamidine: a Cohort Study
Visceral leishmaniosis (VL) is widely reported in Ethiopia, with about 30% of cases being associated with human immunodeficiency virus (HIV).
- Trial name
- NCT01360762
- Testing
- Pentamidine
- Where
- 3 sites in Ethiopia
- Volunteers
- 74 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Advanced Solid Tumor, Unresectable Solid Tumor
A Beta-only IL-2 ImmunoTherapY Study
This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a…
- Conditions
- Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer
- Trial name
- ABILITY-1 (NCT05086692)
- Testing
- MDNA11, Pembrolizumab (KEYTRUDA®)
- Where
- 25 sites in United States, Australia and 6 more
- Volunteers
- 160 people
- Sponsor
- Medicenna Therapeutics, Inc.